No abstract

The problem of atherothrombosis and associated diseases is examined here. The estimation of an enteric form of acetylsalicylic acid (a drug Thrombo ASS) from the perspective of evidence-based medicine is also discussed. The use of acetylsalicylic acid in primary and secondary prevention of cardiovascular diseases is demonstrated.

The problem of chronic tonsillitis (CT), its complications and associated diseases with positions of ENT doctor and cardiologist. The etiology and pathogenesis are also presented, as well as chemotherapy and clinical manifestations of conjugate pathology. A modern classification of CT is also presented. We consider the diagnosis of CT and related diseases.

The article presents data from clinical trials that have examined the efficacy and safety of modern calcium antagonist (CA) III generation of lercanidipine. The results of studies show that treatment with lercanidipine leads to a marked reduction in systolic and diastolic blood pressure without significant effect on heart rate. Unique pharmacokinetic characteristics of the drug provide its excellent efficacy and safety, good tolerability, convenience, acceptance and high adherence CA data in patients with hypertension. Additional properties of lercanidipine allow us to recommend the use of the CA in comorbidity.

The paper presents the study of a new anti-anginal drug - sodium channel inhibitor ranolazine. Considered antianginal, anti-ischemic effect of the drug. Described reduction in angina attacks, increased exercise tolerance and quality of life of patients with stable angina during treatment with ranolazine. Discusses indications, contraindications, side effects, as well as the major clinical trials of the drug ranolazine in patients with coronary heart disease.